Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD) Accessibility StatementSkip Navigation Addresses a Significant Unmet Need in Japan as First and Only Approved Treatment Option for GAD PITTSBURGH, March 23, 2026 /PRNewswire/ -- Viatris Inc.(Nasdaq: VTRS), a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Effexor® SR 37.5 mg / 75 mg capsules (venlafaxine hydrochloride), ...

Investor Event Our Path to Sustained Revenue and Earnings Growth Through 2030 March 19, 2026 Forward Looking Statements This presentation contains "forward-looking statements". These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, statements about: 2026 financial guidance; long-term financial targets; base case long-term target CAGR of 3-4% for Total Revenues, 4-5% for Adjuste ...

Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030 Accessibility StatementSkip Navigation PITTSBURGH, March 19, 2026 /PRNewswire/ -- Viatris Inc.(Nasdaq: VTRS) will host its Investor Event today, where members of the executive leadership team will outline the Company's strategic vision, key drivers and financial framework expected to deliver sustained revenue and earnings growth through 2030. Executive Commentary "Over the past several years, we have taken decisive actions ...